FdaApplication
NDA 217188
Identifiers
- fda_app_no: NDA217188
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER INC |
| application_type | NDA |
| approval_date | 2023-05-25 |
Revenue by product
PAXLOVID (COPACKAGED)
| Period | Revenue |
|---|---|
| Q2 2026 | $21.0M* |
| Q1 2026 | $186.0M* |
| Q3 2025 | $1.2B* |
| Q2 2025 | $427.0M* |
| Q1 2025 | $491.0M* |
| Q3 2024 | $3.1B* |
| Q2 2024 | $251.0M* |
| Q1 2024 | $2.0B* |
| Q3 2023 | $202.0M* |
| Q2 2023 | $286.0M* |
| Q1 2023 | $8.1B* |
| Q4 2022 | $1.8B* |
| Q3 2022 | $15.0B* |
| Q2 2022 | $8.1B* |
| Q1 2022 | $1.5B* |
| Q4 2021 | $76.0M* |
| Q3 2021 | $0.0M* |
| Q2 2021 | $0.0M* |
| Q1 2021 | $0.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PAXLOVID (COPACKAGED) | NIRMATRELVIR; RITONAVIR | 150MG;100MG | TABLET;ORAL |
| PAXLOVID (COPACKAGED) | NIRMATRELVIR; RITONAVIR | 300MG;100MG | TABLET;ORAL |
2 products